evitria Opens its New Head Office in Scandinavia

12-Nov-2019 - Denmark

evitria AG announces the opening of its new head office in Denmark to better serve the growing demand from Scandinavian enterprises. evitria's Nordic office will be headed by Simon Asbjørn Larsen, PhD as Director, Client Relations.

Dr. Larsen specialized in recombinant antibody technology during his doctoral degree at Aarhus University, Denmark. He has since merged his scientific background with commercial roles within the antibody research field and has focused on accelerating antibody discovery and research with partners at pharmaceutical companies, CROs and research institutions.

evitria, headquartered in Schlieren, Zurich (Switzerland), specializes in CHO-based transient expression of recombinant antibodies (including bispecific and fusion antibodies) for research purposes.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous